Shares of medical device company DexCom (NASDAQ:DXCM) fell 7.4% in the morning session after a short-seller report from Hunterbrook Capital alleged issues with the company's G7 glucose monitoring ...

DexCom is down 2.6% since the beginning of the year, and at $76.47 per share, it is trading 15.7% below its 52-week high of $90.75 from February 2025. Investors who bought $1,000 worth of DexCom’s ...

Dexcom on Monday announced its new over-the-counter continuous glucose monitor Stelo is officially available for purchase in the U.S. Glucose is a type of sugar people receive from food, and it's the ...

SAN DIEGO--(BUSINESS WIRE)-- This World Diabetes Day, DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing technology, is encouraging people with diabetes globally to take the first ...

Fintel reports that on October 1, 2025, Goldman Sachs maintained coverage of DexCom (NasdaqGS:DXCM) with a Buy recommendation ...

Deep-pocketed investors have adopted a bearish approach towards DexCom (NASDAQ:DXCM), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled ...

Despite recent share price weakness, the analyst community remains generally optimistic about DexCom's prospects. The average price target among market experts sits around $98, substantially above ...

Dexcom faces mounting scrutiny over G7 safety concerns, FDA violations, financial practices, and growing competition from Abbott's Libre 3.

Fintel reports that on September 29, 2025, Canaccord Genuity maintained coverage of DexCom (NasdaqGS:DXCM) with a Buy ...

Often, when dealing with fast-growing companies trading at what seem to be elevated multiples, I add that the margin of error is small. After all, a high valuation ...

Glucose is a type of sugar people receive from food, and it's the body's main source of energy. Continuous glucose monitors, or CGMs, are small sensors that poke through the skin to measure glucose ...